// App-Quantinova.ai

4054 : Efficacy and Safety Of Pegelated Interferon alpha2a once Monthly Compared To Once Weekly Dose In Patients With Essential thrombocythemia

Researchers

Presenter

  • Mohamed A. Yassin

Principal Investigators

  • Nader I Al-Dewik

  • Hanadi El Ayoubi

  • Bruno Cassinat

Medical Centers

  • Hematology/BMT, National Center for Cancer Care and Research-HMC, DOHA, Qatar

  • Unite de Biologie Cellulaire, AP-HP, Hopital Saint-Louis, Paris, France

Locations

  • France

  • Qatar

Companies

  • Hamad Medical Corpor

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Autoimmune hepatitis

  • Congestive heart failure

  • Renal insufficiency

  • Depression

  • Venous thrombosis

Biomarkers

  • Breakpoint Cluster Region

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Interferon

Drug/Treatment

  • Albyl-E

  • Hydroxyurea

  • Hydroxycarbamide

  • Anagrelide hydrochloride

  • Interferon

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved